March 15th 2023
Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein.
March 11th 2023
Novel gene therapy shows promise for treating multiple eye diseasesFebruary 3rd 2023
The results are consistent with those observed, and previously published by the same group, showing benefit in age related macular degeneration models and highlights the potential value of ophNdi1 for multiple eye diseases.
Eyenovia offers results of study evaluating microdose delivery technologyJanuary 12th 2023
According to the company, gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride treatment administered via the company’s microdose formulation decreased inflammation from preserved glaucoma solutions compared to drops.
Frontera Therapeutics doses first patient in clinical trial for gene therapy FT-001 for treatment of LCAJanuary 6th 2023
FT-001 is administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.
Janey Wiggs, MD, PhD, associate chief of Ophthalmology Clinical Research at Massachusetts Eye & Ear discusses genetics of glaucoma, providing an overview of what is known about genes and gene mutations that can cause or contribute to glaucoma.
Opus Genetics pays $500,000 upfront for rights to pair of gene therapy product candidates for inherited retinal diseasesDecember 29th 2022
According to a news release, Opus will advance preclinical development programs for BEST1– and RHO-related retinal diseases. The deal expands the company’s addressable patient population for its novel treatments for rare inherited retinal diseases.
Opus Genetics receives FDA Clearance of IND application for OPGx-001 for treatment of retinal disease LCA5December 3rd 2022
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision loss due to mutations in the LCA5 gene, which causes one of the most severe forms of early-onset blinding disease Leber congenital amaurosis.
NIH scientists discover essential step in recharging the retinaOctober 27th 2022
A previously uncharacterized area of the protein known as RPE65 spontaneously turns spiral-shaped when it encounters intracellular membranes, or thin structures that surround different parts of a cell.
UCI-led report illustrates potential of precision genome editing in treating inherited retinal diseasesOctober 13th 2022
According to University of California, Irvine researchers, current preclinical successes and clinical genome editing approaches for treating inherited retinal degenerative disease and stresses there is hope that in vivo gene editing will be the future treatment paradigm for these diseases.
Nanoscope Therapeutics receives fast track designation from FDA for MCO-010 for treatment of retinitis pigmentosaOctober 12th 2022
Nanoscope Therapeutics Inc. announced the FDA has granted Fast Track Designation to MCO-010, an ambient-light activatable multi-characteristic opsin optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa via intravitreal injection.
Study: Gene therapy rapidly improves night vision in adults with congenital blindnessOctober 11th 2022
According to a study by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania, patients’ low-light sensitivity improved by factors of thousands in a clinical trial.
NIH backing first-in-class engineered mechanosensitive channel based gene therapy for glaucomaOctober 9th 2022
Nanoscope Technologies LLC announced this week it has received Direct Phase II SBIR grant from National Institutes of Health for developing an innovative approach to autonomously regulate pressure for treatment of Glaucoma in a gene-agnostic manner.